Apellis Pharmaceuticals Inc

NASDAQ:APLS   12:00:09 PM EDT
63.22
+1.46 (+2.36%)
Regulatory, Earnings Announcements

Apellis Announces 24-Month Results Showing Increased Effects Over Time With Pegcetacoplan In Phase 3 Derby And Oaks Studies In Geographic Atrophy

Published: 08/24/2022 12:13 GMT
Apellis Pharmaceuticals Inc (APLS) - Apellis Announces 24-month Results Showing Increased Effects Over Time With Pegcetacoplan in Phase 3 Derby and Oaks Studies in Geographic Atrophy (ga).
Apellis Pharmaceuticals Inc - Consistent With Expectations, No Clinically Meaningful Difference on Key Functional Endpoints Observed at 24 Months.
Apellis Pharmaceuticals Inc - Potential to Become First-ever Treatment for Ga With a U.S. PDUFA Date of Nov.
26, 2022.
Apellis Pharmaceuticals Inc - Eu Marketing Authorization Application Submission on Track by End of Year.
Revenue is expected to be $21.74 Million
Adjusted EPS is expected to be -$1.45

Next Quarter Revenue Guidance is expected to be $26.8 Million
Next Quarter EPS Guidance is expected to be -$1.55

More details on our Analysts Page.